The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol

The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol

Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. Whether spironolactone, a mineralocorticoid receptor antagonist, improves outcomes for patients receiving maintenance dialysis is unclear. Ob...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Walsh, David Collister, Martin Gallagher, Patrick B. Mark, Janak R. de Zoysa, Jessica Tyrwhitt, Karthik Tennankore, Laura Sola, Gilmar Reis, Denis Xavier, Russell Villanueva, Wen J. Liu, Camilo Félix, Li Zuo, Mustafa Arici, Vivekanand Jha, Ron Wald, Amanda Y. Wang, Atiya R. Faruqui, Fei Yuan, Shun Fu Lee, Alena Kuptsova, Courtney Christou, P. J. Devereaux
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:Canadian Journal of Kidney Health and Disease
Online Access:https://doi.org/10.1177/20543581251348187
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/20543581251348187

Similar Items